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Abstract 
Background: C14orf166 (chromosome 14 open reading frame 166) plays a crucial role in some tumors, but its role in 
bladder cancer hasn’t been explored.
Method: We determined C14orf166 expression in uroepithelial cell, bladder cancer cells, normal bladder tissues 
and bladder cancer tissues using quantitative RT-PCR and western blot, we then analyzed the correlation between 
C14orf166 expression and clinicopathologic characteristics in a cohort of 149 patients with bladder cancer. Finally we 
downregulated C14orf166 and determined its role in the proliferation of bladder cancer cell lines using MTT assay, 
colony formation assay and cell cycle assay.
Results: We demonstrated C14orf166 was upregulated in bladder cancer cells and tissues, C14orf166 expression was 
significantly correlated with larger tumor size (P = 0.001), lymph node involvement (P < 0.001), histological differen-
tiation (P < 0.001), survival time and vital states, and high C14orf166 expression correlated with poor survival, these 
results suggested C14orf166 served as a high-risk marker for bladder cancer. Knockdown of C14orf166 decreased the 
proliferation rate and colony formation ability of bladder cancer cells, and arrested cell cycle in G1/S transition. Further 
analysis showed that C14orf166 knockdown caused abnormal expression of key proteins for G1/S transition, such as 
Cyclin D1, P21, P27 and Rb phosphorylation.
Conclusions: This study demonstrates that C14orf166 promotes bladder cancer cell proliferation and can be a novel 
prognostic biomarker for patients with bladder cancer.
Keywords: Bladder cancer, C14orf166, Prognosis, Cell proliferation, G1/S phase
© 2016 Chen et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Bladder cancer is a common genitourinary tumor world-
wide [1]. It is classified into two types with distinct 
molecular characteristics and clinical outcomes accord-
ing to the tumor-node-metastasis (TNM) system. Non-
muscle-invasive bladder cancer (stage Ta, carcinoma 
in  situ) accounts for 60  % of bladder cancer diagnoses, 
and morbidity is very high (50–70 %), its ability to metas-
tasize is very low; the 5-year survival rate is very high, i.e., 
up to 90 %. Muscle-invasive bladder cancers (≥stage T1) 
have high ability to metastasize, and the 5-year survival 
rate is  <50  % [2, 3]. To date, it has been reported that 
some oncogenes play crucial role in the progression of 
bladder cancer, such as fibroblast growth factor receptor 
3 (FGFR3) [4, 5], DEP domain–containing 1 (DEPDC1) 
[6], M-phase phosphoprotein 1 (MPHOSPH1) [7], and 
P73 [8]. Chemotherapy drugs have also been developed 
for bladder cancer therapy, such as methotrexate, vin-
blastine, doxorubicin, and cisplatin [9, 10]. However, 
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therapy of bladder cancer remains a challenge. Identify-
ing new genes that promote or suppress bladder cancer 
development will benefit for bladder cancer therapy.
C14orf166 (is also known CLE or CGI-99), which 
interacts with the PA subunit of the influenza virus pol-
ymerase complex [11], is essential in regulation of viral 
polymerase activity, viral RNA transcription and replica-
tion, and viral particle production [12]. Proteomics anal-
ysis has found that C14orf166 interacts with a hepatitis 
C virus core protein (HCVc), HCVc174, suggesting that 
C14orf166 modulates replication and function of HCV 
[13]. Apart from its role in regulation of RNA polymer-
ase activity, C14orf166 promotes development in some 
tumors. A comparison of the protein expression profiles 
between pancreatic cancer clinical samples found that 
C14orf166 levels were higher in samples with lymph 
node metastasis (LNM) than in non-LNM samples. This 
suggests that C14orf166 may promote pancreatic cancer 
metastasis [14]. Howng and colleagues found C14orf166 
is high expression in brain tumors, and it blocked ninein 
phosphorylation by glycogen synthase kinase-3β (GSK3β) 
[15]. Recently, C14orf166 is demonstrated to correlate 
with disease progression and poorer outcome in uterine 
cervical cancer and nasopharyngeal carcinoma [16, 17]. 
However, the role of C14orf166 in bladder cancer has 
not been investigated. JAK2/STAT3 signaling promotes 
bladder cancer progression [18], Xuting Chen et al. [19] 
found JH2 domain of JAK2 interact with C14orf166, we 
thought C14orf166 might regulate the progression of 
bladder cancer.
Here, we studied the role of C14orf166 in bladder can-
cer, aiming to identify a new target for bladder cancer 
therapy. We found that C14orf166 was upregulated in 
bladder cancer cells and tissues compared with normal 
bladder cells and tissues. High C14orf166 expression was 
correlated with poor patient survival, and based on anal-
ysis of the clinicopathologic characteristics, C14orf166 
expression might be a novel prognostic factor for bladder 
cancer. Tetrazolium (MTT) and colony formation assays 
revealed that C14orf166 knockdown suppressed cellular 
proliferation, further analysis found that C14orf166 was a 
key regulator of G1/S transition.
Methods
Cell lines and cell culture
Bladder cancer cells J82, UM3, RT4, 5637 and T24 were 
cultured in RPMI 1640 medium (Gibco, Grand Island, 
NY, USA), supplemented with 10  % fetal bovine serum 
(Gibco), 2 mM l-glutamine (Gibco), 100 μM non-essen-
tial amino acids (NEAA), 50 U/mol penicillin, 50 mg/ml 
streptomycin. Immortalized human uroepithelial cell, 
SV-HUC-1, was cultured in RPMI 1640 medium, supple-
mented with 10 % fetal bovine serum, 50 U/mol penicillin 
and 50 mg/ml streptomycin. All of cells were purchased 
from American Type Culture Collection (ATCC), and 
were maintained in a humidified atmosphere at 37  °C 
with 5 % CO2.
Human bladder cancer specimens
Paraffin-embedded bladder cancer samples were 
obtained from a cohort of 149 Chinese patients diag-
nosed with bladder cancer in 2001–2012 at Cancer 
Center, Sun Yat-sen University, Guangdong Province, 
People’s Republic of China. The detailed information 
was presented in Table 1. Clinical and pathologic factors 
were determined, age, gender, TNM classification, degree 
of differentiation, tumor number, vital states, tumor size 
and Recurrence were included. Six fresh bladder tumor 
tissues which and adjacent bladder tissues were also col-
lected from the same place. The tissues were frozen and 
stored in liquid nitrogen until further use. All samples 
were obtained with informed consent and approved by 
the Guangdong General Hospital Ethics Committee.
Small interfering RNAs (siRNAs), RNA extraction 
and quantitative RT‑PCR
In order to knock-down the expression of C14orf166, 
two C14orf166 siRNAs and their cognate control siR-
NAs (Scramble) were synthesized by Guangzhou RiboBio 
Co (Guangdong, China). 20 nm siRNA were transfected 
into indicated cells in six plates using Lipofectamine 
RNAiMax Reagent (Life Technologies) according to the 
manufacturer’s instruction. Total RNA from cultured 
cells and surgical fresh bladder tumor tissues and adja-
cent bladder tissues were extracted using Trizol (Life 
technologies) according to manufacturer’s instructions. 
cDNA was synthesized from total RNA using ReverTra 
Ace qPCR RT Kit (TOYOBO). Relative expressions of 
different genes were detected using SYBR Green PCR Kit 
(Roche) with the GAPDH gene as an internal reference. 
The PCR reactions were run using ABI 7500 Real- time 
PCR System. The comparative Ct method (ΔΔCt) was 
used to calculate the relative expression levels.
Western blot and immunohistochemistry (IHC)
Total protein was extracted from cells using RIPA buffer 
(P00013C, Beyotime), protein concentration was meas-
ured using the BCA protein assay kit (pierce). 30 ug pro-
teins were loaded. Western blot analysis was performed 
as described [20]. Primary antibodies against C14orf166 
(Abcam, ab188326), CyclinD1, P21, P27, retinoblastoma 
(Rb) and p-Rb were purchased from Santa Cruz Bio-
technology. These antibodies were used at a dilution of 
1:1000. An antibody to human α-Tubulin (1:5000, Santa 
Cruz) was used as a loading control. Immunohistochem-
istry which was used to determine the expression of 
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C14orf166 in bladder cancer tissues and adjacent bladder 
tissues was performed according to previous report [21], 




Cells, seeded on 96-well plates, were stained at indi-
cated time points with 20ul sterile MTT dye (5  mg/ml, 
Sigma) for 4 h at 37  °C, followed by removal of the cul-
ture medium and addition of 150ul of DMSO (Sigma). 
The absorbance was measured at 570, and 655 nm as the 
reference wavelength. All experiments were performed in 
triplicates.
Colony formation assay
Cells were seeded on 6-well plates at a density of 
0.5 × 103 cells per well, and cultured for 10 days. Colo-
nies were fixed with 10  % formaldehyde for 5  min and 
then stained with 1.0 % crystal violet for 30 s.
Cell cycle assay
Cell cycle assay was performed according to the standard 
method described previously. Briefly, cells were collected 
and washed by cold PBS, and fixed with 70  % ethanol 
for overnight at 4  °C, then cells were washed using cold 
PBS for three times, and resuspended in PBS buffer con-
taining 100 U/ml RNase A and 50 ug/ml PI at 37 °C for 
30  min. Samples were analyzed using BD FACSCalibur 
cytometer.
Statistical analysis
All cellular experiments were done at least three repeated, 
and results were described as the mean ± standard devi-
ation (STDEV) using SPSS version 10.0 software (SPSS, 
Chicago, IL. USA). Statistical differences were deter-
mined by using ANOVA and student’s t test for inde-
pendent samples. Chi square test was used to determine 
the differences in the expression of C14orf166 between 
the two categories of tissues. It was used to calculate the 
p values to indicate the correction between clinical fea-
tures and C14orf166 expression in bladder cancer. Rela-
tive risks of death associated with C14orf166 expression 
and other predictive variables, such as the T classifica-
tion, were estimated by using the univariate and multi-
variate Cox-regression analysis. Kaplan–Meier Survival 
analysis and the log-rank test were used to plot overall 
survival curve. A p value of less than 0.05 was considered 
statistically significant.
Results
C14orf166 expression was upregulated in bladder cancer 
cell lines
To determine the role of C14orf166 in bladder cancer, we 
first determined C14orf166 expression in immortalized 
human bladder epithelial SV-HUC-1 cells and in bladder 
cancer cell lines. Both quantitative RT-PCR and west-
ern blotting revealed that C14orf166 was upregulated in 
the bladder cancer cell lines (Fig. 1a, b), suggesting that 
C14orf166 may contribute to the progression of bladder 
cancer.
C14orf166 expression was upregulated in bladder cancer 
tissues
We also determined C14orf166 expression in clinical 
samples of bladder cancer. Both quantitative RT-PCR and 
western blotting revealed that C14orf166 expression was 
higher in tumor tissues than in normal bladder tissues 
Table 1 Clinicopathological characteristics of clinical sam-
ples and  expression of  C14orf166 in  Human bladder can-
cer
Characteristics Number of cases (%)
Age (years)
 <64 81 (47.1)
 ≥64 91 (52.9)
Gender
 Male 156 (90.7)
 Female 16 (9.3)
T classification
 T1 91 (52.9)
 T2 81 (47.1)
N classification
 N0 150 (87.2)
 N1 22 (12.8)
Recurrence
 No 82 (47.7)
 Yes 90 (52.3)
Vital status (at follow-up)
 Alive 67 (39.0)
 Dead 105 (61.0)
Expression of C14orf166
 Low expression 87 (50.6)
 High expression 85 (49.4)
Number
 ≥3 64 (37.2)
 <3 108 (62.8)
Histological differentiation
 Well 32 (18.6)
 Moderate 54 (31.4)
 Poor 86 (50.0)
Tumor size
 ≥3 cm 100 (58.1)
 <3 cm 72 (41.9)
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(Fig.  2a). IHC determined that C14orf166 was upregu-
lated in both T1 and T2 bladder cancer tissues compared 
to the normal bladder tissues, C14orf166 expression in 
the T2 samples was higher than that in the T1 samples 
(Fig. 2b). This indicated that C14orf166 is overexpressed 
in patients with bladder cancer, suggesting that it may 
function as a new prognostic biomarker for bladder 
cancer.
Fig. 1 C14orf166 upregulation in human bladder cancer cell lines. a Quantitative RT-PCR determination of C14orf166 expression in immortalized 
human bladder epithelial SV-HUC-1 cells and bladder cancer J82, UM3, RT4, 5637, and T24 cells. Transcription levels were normalized to GAPDH 
expression. b Western blot determination of C14orf166 expression in SV-HUC-1, J82, UM3, RT4, 5637, and T24 cells. α-Tubulin was used as the load-
ing control. *P < 0.05
Fig. 2 C14orf166 upregulation in bladder cancer tissues. a Quantitative RT-PCR determination of C14orf166 expression in bladder cancer tissues 
and adjacent bladder tissues from six patients. Transcription levels were normalized to GAPDH expression. b Western blot analysis of C14orf166 
expression in bladder cancer tissues and adjacent bladder tissues. α-Tubulin was used as the loading control. c IHC determination of C14orf166 
expression in different patients with different clinical stages of disease according to T classification (magnification: ×200, ×400)
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High C14orf166 expression in primary bladder cancer 
tissues correlated with poor patient survival
To investigate the clinical significance of C14orf166, 
we determined the relationships between C14orf166 
expression and survival in a cohort of 149 patients with 
bladder cancer (Table  1). Kaplan–Meier survival analy-
sis and the log-rank test determined that the overall 
survival of patients with high C14orf166 expression 
Fig. 3 Kaplan–Meier curves with log-rank tests revealed a statistical difference in overall survival. a C14orf166 expression and Kaplan–Meier 
analysis of overall survival (P < 0.001). b and c C14orf166 expression and Kaplan–Meier analysis of overall survival in patients with tumor size <3 cm 
(P < 0.001) (left) and with tumor size >3 cm (P = 0.008) (right), respectively. d and e C14orf166 expression and Kaplan–Meier analysis of overall 
survival in patients with tumor number <3 cm (P < 0.001) and with tumor number >3 (P = 0.001), respectively
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was significantly shorter than that of patients with low 
C14orf166 expression (Fig.  3a). We divided the clini-
cal samples according to the clinicopathologic charac-
teristics, and determined patient survival. Regardless 
of tumor classification T1 and T2, patients with high 
C14orf166 expression had significantly shorter survival 
than those with low C14orf166 expression (Fig.  3b). 
Regardless of tumor number (n = 3), patients with high 
C14orf166 expression also had significantly shorter sur-
vival than those with low C14orf166 expression (Fig. 3c). 
These findings suggest that high C14orf166 expression in 
bladder cancer indicates poor survival.
Clinical significance of C14orf166 expression in bladder 
cancer cases
We determined the correlation between C14orf166 
expression and the clinicopathologic characteristics of 
patients with bladder cancer. Tables  2 and 3 show that 
C14orf166 expression was significantly correlated with 
larger tumor size (P =  0.001), lymph node involvement 
(P  <  0.001), histological differentiation (P  <  0.001), sur-
vival time and vital states, which suggested a correla-
tion between higher C14orf166 expression and clinical 
progression in bladder cancer. However, no significant 
correlation was found for other clinicopathologic charac-
teristics such as age, sex, recurrence, and tumor number.
We also analyzed the role of C14orf166 in the progno-
sis of bladder cancer; we defined a relative risk of 1.000 as 
the baseline in patients with the following characteristics: 
low C14orf166 expression, T1, N0, and good histologi-
cal differentiation. We used Cox regression proportional 
hazard analysis to determine whether C14orf166 could 
be used as a clinical risk factor. Univariate Cox regression 
analysis determined that increased C14orf166 expression 
was associated with significantly increased risk of death 
(P < 0.001), tumor size (P = 0.03), lymph node involve-
ment (P  <  0.001) (Table  4). Multivariate Cox regression 
analysis found that C14orf166 predicted poor survival 
when C14orf166 expression, T classification, N classifica-
tion, and histological differentiation were included in the 
analysis (P < 0.001). Tumor size (P = 0.023) and N clas-
sification (P < 0.001) also predicted unfavorable progno-
sis. These results suggest that C14orf166 is significantly 
correlated with the prognosis of bladder cancer, and is an 
unfavorable prognostic factor for patients with bladder 
cancer.
C14orf166 knockdown inhibited bladder cancer cell 
proliferation
To determine whether C14orf166 regulate cell prolif-
eration, we downregulated its level by siRNAs. Western 
blotting and quantitative RT-PCR determined that the 
two siRNAs downregulated C14orf166 expression effec-
tively in the RT4 and T24 bladder cancer cell lines com-
pared to Scramble (Fig. 4a, b).
MTT assay revealed that C14orf166 knockdown reduced 
the proliferation rate of the two indicated bladder cancer 
cell lines (Fig. 4c). Colony formation assay determined that 
Table 2 The correlation between  C14orf166 expression 
and  clinicopathologic characteristics of  bladder cancer 
patients







 <64 81 41 40 0.993
 ≥64 91 46 45
Gender
 Male 156 78 78 0.634
 Female 16 9 7
T classification
 T1 91 72 19 <0.001
 T2 81 15 66
N classification
 N0 150 85 65 <0.001
 N1 22 2 20
Recurrence
 Yes 90 39 51 0.046
 No 82 48 34
Histological differentiation
 Well 32 27 5 <0.001
 Moderate 54 42 12
 Poor 86 18 68
Number
 ≥3 63 34 30 0.608
 <3 108 53 55
Vital status (at follow-up)
 Alive 67 52 15 <0.001
 Dead 105 35 70
Table 3 Spearman correlation analysis between C14orf166 
and clinical pathologic factors
Variables C14orf166 expression level
Spearman correlation P value
Survival time −0.413 <0.001
Vital status 0.432 <0.001
T classification 0.605 <0.001
N classification 0.318 <0.001
Histological differentiation 0.551 <0.001
Recurrence 0.152 0.047
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downregulating C14orf166 also decreased cell numbers 
significantly (Fig. 4d). These results suggest that C14orf166 
promotes bladder cancer cell proliferation.
C14orf166 regulated bladder cancer cell proliferation 
by promoting G1/S transition
We further determined if C14orf166 contributes to cell 
proliferation through regulating cell cycle proliferation, 
and found knockdown of C14orf166 increased the pop-
ulation of G1 phase, and decreased the population of S 
phase (Fig. 5a). We further determined the expression of 
cell cycle regulatory proteins that control G1/S transition. 
We downregulated C14orf166 using siRNAs, and both 
quantitative RT-PCR and western blotting revealed that 
Cyclin D1 expression was downregulated significantly 
and P21 and P27 expression was upregulated signifi-
cantly upon C14orf166 knockdown in RT4 bladder can-
cer cells. Rb phosphorylation levels were also decreased, 
but Rb expression was unaltered (Fig.  5b, c). C14orf166 
knockdown in T24 cells also downregulated Cyclin D1 
significantly and upregulated P21 and P27 significantly; 
Rb phosphorylation was also reduced (Fig. 5d, e). These 
results suggest that C14orf166 controls cell proliferation 
by regulating the proteins that control G1/S transition.
Discussion
We found that C14orf166 expression is upregulated in 
bladder cancer cell lines and in primary bladder cancer 
tissues. C14orf166 promoted cell proliferation by regulat-
ing the key regulatory proteins of G1 progression. Dis-
rupted cell cycle control is one of the primary causes of 
cancer development, where individuals with abnormal 
expression of the cell cycle control genes have increased 
risk for bladder cancer [22]. C14orf166 regulates the 
cell cycle checkpoint proteins, suggesting that it may be 
a key regulator of bladder cancer progression. We also 
demonstrated that C14orf166 was associated with clini-
cal characteristics such as tumor size and survival time. 
High C14orf166 expression predicted unfavorable prog-
nosis and low survival rate. These results suggested that 
C14orf166 not only functions as an oncogene but also as 
a novel prognostic biomarker for patients with bladder 
cancer. This study also demonstrated a new function of 
C14orf166 in tumor biology.
There are some prognostic biomarkers for bladder can-
cer, such as tumor protein 53 (TP53), P21, and tuberous 
sclerosis 1 (TSC1), but these genes only apply to a fraction 
of bladder cancer patients [23]. Therefore, screening new 
prognostic biomarkers is essential. We analyzed the rela-
tion between C14orf166 and the clinicopathologic param-
eters of a cohort of 172 clinical samples, and found lower 
survival rates in patients with high C14orf166 expression 
compared to patients with low C14orf166 expression. 
C14orf166 might combine with other clinical biomarkers 
to help identify patients with higher rates of survival.
C14orf166 is mapped to 14q22.1, and interacts with 
protein tyrosine phosphatase–interacting protein 51 
(PTPIP51) to impact normal mitotic processes and chro-
mosomal division [24]. It also interacts with human ninein 
(hNinein), a centrosome component, and inhibits hNi-
nein phosphorylation, which suggests that C14orf166 
may participate in centrosome architecture and regulate 
the formation of the centrosome, which plays a vital role 
in cell cycle progression, thus C14orf166 may regulate cell 
Table 4 Univariate and multivariate analyses of various prognostic parameters in patients with bladder cancer by Cox-
regression analysis
Univariate analysis Multivariate analysis
No. patients P Regression  
coefficient (SE)
P Relative risk 95 % Confidence 
interval
C14orf166
 Low expression 87 <0.001 1.697 (0.312) <0.001 5.456 2.962–0.047
 High expression 85
T classification
 T1 91 0.010 −0.584 (0.263) 0.027 0.558 0.333–0.935
 T2 81
N classification
 N0 150 <0.001 1.157 (0.285) <0.001 3.180 1.818–5.564
 N1 22
Histological differentiation
 Well 32 0.056 −0.329 (0.154) 0.032 0.720 0.553–0.972
 Moderate 54
 Poor 86
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cycle in this manner [15]. To test the role of C14orf166 
in the progression of bladder cancer, we downregulated 
C14orf166 expression in bladder cancer cells, and found 
that C14orf166 promoted bladder cancer cell prolifera-
tion. We further analyzed the expression of key regulatory 
proteins of G1/S transition, finding that Cyclin D1, P21, 
and P27 were downregulated. Cyclin D determines the 
duration of the G1 phase, and is present in three subtypes: 
Cyclin D1, Cyclin D2, and Cyclin D3 [25]. Cyclin D1 down-
regulation arrests cell in G1 phase. Cyclin D1 also binds to 
cyclin-dependent kinase (CDK) 2, CDK4, and CDK6 to 
form an active complex that phosphorylates Rb. Rb phos-
phorylation accelerates G1/S transition [26]. In our study, 
Rb phosphorylation was decreased. P21 and P27 are cyclin 
kinase inhibitors, which inhibit cell cycle progression [27, 
28]. After C14orf166 knockdown, we found that P21 and 
P27 expression was upregulated. These findings suggest 
that C14orf166 promotes cell proliferation by accelerating 
G1/S transition. However, the role of C14orf166 in apop-
tosis and cell migration remains to be defined in vitro and 
in vivo. The in-depth mechanism of C14orf166 in tumori-
genesis remains to be elucidated.
Fig. 4 C14orf166 knockdown inhibited the proliferation of bladder cancer cell lines. a Western blot determination of the effect of C14orf166 siRNAs 
in bladder cancer RT4 and T24 cells. b Quantitative RT-PCR determination of the effect of C14orf166 siRNAs in bladder cancer RT4 and T24 cells. 
Transcription levels were normalized to GAPDH expression. c MTT assay determination of bladder cancer RT4 and T24 cell proliferation following 
C14orf166 downregulation. d Colony formation assay determination of the effect of C14orf166 downregulation on cell proliferation. *P < 0.05
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Conclusions
In summary, these data demonstrate that C14orf166 
could be a prognostic factor for bladder cancer, and pro-
motes cell proliferation by accelerating G1/S transition.
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